Gallantt Ispat Limited has informed the Exchange regarding Board meeting held on November 03, 2025.
GALLANTT · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gallantt Ispat's Board approved unaudited Q2/H1 FY26 results (ended Sept 30, 2025) along with a limited review report from statutory auditor M/s Maroti & Associates. On a standalone basis, Q2 revenue rose about 15% year-on-year to roughly Rs. 1,293 crore, while Q2 profit after tax jumped nearly 78% to around Rs. 87 crore; H1 FY26 PAT came in at about Rs. 261 crore, up roughly 53% over the same period last year. The Board also approved selling its entire stake in two associate companies – Gallantt Medicity Devlopers (Rs. 7.80 crore) and Gallantt Lifespace Devlopers (Rs. 81.90 crore) – to Gallantt Fincares Pvt Ltd, a promoter group entity, with completion targeted by Nov 30, 2025. Separately, the company announced an 18 MW solar power plant in Gujarat with an estimated investment of Rs. 48.25 crore, expected to be operational by May 31, 2026.
Sharp year-on-year jump in quarterly profit signals strong operating momentum and should support the stock, though the two related-party divestitures of associates to a promoter group company worth about Rs. 89.7 crore may draw governance scrutiny from minority shareholders. The solar power capex of Rs. 48.25 crore is a step towards lower long-term power costs and ESG alignment.